Advanced Melanoma Global Market Report 2025

The advanced melanoma market size has grown strongly in recent years. It will grow from $3.77 billion in 2024 to $4.13 billion in 2025 at a compound annual growth rate (CAGR) of 9.4%. The growth during the historic period can be attributed to the approval of dacarbazine, the development of interferon therapy, the introduction of ipilimumab, the adoption of radiation therapy, the emergence of combination therapies, the approval of nivolumab, and the launch of pembrolizumab.

The advanced melanoma market size is expected to see strong growth in the next few years. It will grow to $5.9 billion in 2029 at a compound annual growth rate (CAGR) of 9.3%. The growth during the forecast period can be attributed to the development of novel checkpoint inhibitors, the rise of personalized medicine, advancements in adoptive cell therapy, the increasing use of combination therapies, the emergence of bispecific antibodies, the expansion of oncolytic virotherapy, and a growing focus on early detection tools. Major trends include AI-powered diagnostic tools, mRNA-based cancer vaccines, CRISPR-based gene editing, oncolytic virus engineering, liquid biopsy technologies, wearable health monitoring devices, advanced imaging techniques, 3D bioprinting for research, tumor microenvironment modeling, and nanotechnology-driven drug delivery systems.

The rising incidence of severe sunburns is expected to drive the expansion of the advanced melanoma market. Severe sunburns occur due to excessive exposure to ultraviolet (UV) radiation, leading to redness, pain, swelling, and sometimes blistering. The increasing frequency of severe sunburn cases is attributed to prolonged UV exposure, inadequate sun protection, increased outdoor activities during peak UV hours, and rising global temperatures due to climate change. Repeated or childhood sunburns cause DNA damage in skin cells, potentially leading to genetic mutations that trigger melanoma. For example, in May 2024, Melanoma Focus, a UK-based charity supporting the melanoma community, reported that in 2022-23, there were 201 hospital admissions due to sunburn, including 89 children and 25 infants under one year old. Additionally, 66% of UK adults aged 16-65 recalled experiencing sunburn as children, while 65% had suffered severe sunburn with blistering at least once, a figure that rose to 77% for individuals with fair skin. Consequently, the growing number of severe sunburn cases is driving the advanced melanoma market forward.

Leading companies in the advanced melanoma market are prioritizing the development of innovative treatments, such as personalized vaccines, to enhance treatment efficacy, address resistance mechanisms, and offer tailored therapies that improve patient outcomes and survival rates. A personalized vaccine for advanced melanoma is designed for individual patients based on the unique genetic mutations in their tumors. For instance, in April 2023, Merck & Co. Inc., a US-based pharmaceutical company, and Moderna Inc., a US-based biotechnology company, received Priority Medicines (PRIME) scheme designation from the European Medicines Agency (EMA) for their investigational personalized mRNA cancer vaccine, mRNA-4157/V940. This vaccine, when combined with Merck’s anti-PD-1 therapy, KEYTRUDA (pembrolizumab), is intended for the adjuvant treatment of high-risk stage III/IV melanoma patients following complete tumor resection. The mRNA-4157/V940 vaccine contains a single synthetic mRNA encoding up to 34 neoantigens and is custom-designed based on each patient’s unique tumor mutation profile.

In December 2023, Pfizer Inc., a US-based pharmaceutical company, acquired Seagen Inc. for $43 billion. This acquisition doubled Pfizer’s oncology pipeline, expanding it to 60 programs across various treatment modalities. By integrating Seagen’s antibody-drug conjugate (ADC) technology, Pfizer aims to leverage its expertise in protein engineering and medicinal chemistry to develop novel therapeutic combinations and next-generation biologics. Seagen Inc., a US-based biotechnology company, specializes in researching and developing treatments for advanced melanoma, with a strong focus on ADC technology.

Major players in the advanced melanoma market are Pfizer Inc., F Hoffmann-La Roche Ltd, Merck & Co. Inc., Bristol-Myers Squibb, AstraZeneca AG, Novartis AG, GlaxoSmithKline Plc, Amgen Inc., BioNTech SE, Regeneron Pharmaceuticals, Genentech Inc., Exelixis Inc., Dynavax Technologies, Replimune Group, Immunocore Holdings plc, Xencor Inc., Agenus Inc., Nektar Therapeutics, Iovance Biotherapeutics, Adaptimmune Therapeutics, Immutep Ltd., Lytix Biopharma.

North America was the largest region in the advanced melanoma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in advanced melanoma report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the advanced melanoma market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Advanced melanoma is a type of melanoma skin cancer that has spread from its original location to other areas of the body. It includes stage III, where the cancer has reached nearby lymph nodes, and stage IV, where it has metastasized to distant organs. Treating advanced melanoma is more complex and often requires a combination of therapies, such as immunotherapy, targeted therapy, chemotherapy, or radiation.

The primary treatment approaches for advanced melanoma include chemotherapy, biological therapy, targeted therapy, and immunotherapy. Chemotherapy involves the use of drugs to eliminate or inhibit the growth of rapidly dividing cancer cells. The various distribution channels for these treatments include hospital pharmacies, online pharmacies, and retail pharmacies. Additionally, multiple end-users benefit from these therapies, including hospitals, cancer research centers, academic institutions, diagnostic centers, ambulatory surgical centers, and others.

The advanced melanoma market research report is one of a series of new reports that provides advanced melanoma market statistics, including advanced melanoma industry global market size, regional shares, competitors with an advanced melanoma market share, detailed advanced melanoma market segments, market trends and opportunities, and any further data you may need to thrive in the advanced melanoma industry. This advanced melanoma market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The advanced melanoma market consists of revenues earned by entities by providing services such as diagnosis and staging, surgical excision, immunotherapy administration, targeted therapy management, palliative care and support services. The market value includes the value of related goods sold by the service provider or included within the service offering. The advanced melanoma market also includes sales of pembrolizumab, vemurafenib, trametinib, and personalized cancer vaccines. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.